Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD

Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.

24/7 Wall Street • Aug 19, 2026

Virginia and Texas Are About to Become Cannabis Battlegrounds. Here's Which Stocks Are Positioned to Win.

Limited-license states often favor established cannabis operators. Scale and positive cash flow create lasting competitive advantages.

The Motley Fool • Aug 7, 2026

The Marijuana Industry Just Had a Massive Milestone

Trulieve Cannabis is a leading company in the marijuana market, and it's now trading on a major U.S. exchange. As the U.S. government has rescheduled medical marijuana products, it has paved the way for Trulieve to uplist onto the New York Stock Exchange.

The Motley Fool • Jun 16, 2026

Marijuana Stocks to Watch Before the Next Cannabis Rally

The cannabis sector continues to attract investors seeking long-term growth opportunities in 2026. Although volatility remains high, many marijuana companies are improving operations and cutting costs. At the same time, investors continue watching potential federal reform closely. Rescheduling discussions and banking reform could become major catalysts for the industry.

3 Top Picks For Marijuana Stocks Investors To See Profits In 2026

For marijuana stock investors, the way the industry as a whole progresses determines a great deal for them. For example, no one wants to invest in a struggling industry even if it's been trendy along the way. Now, cannabis has fallen to that path, but it's also what's making this industry one of the hottest sectors in the last 5 years. Legal cannabis has been a long uphill battle in every sense. Legislation and regulatory issues remain the biggest challenges.

Trump's Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs

After amassing enormous losses over the past five years, cannabis stocks received a much-needed shot in the arm last week when President Donald Trump announced plans to officially reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

MarketBeat • May 3, 2026

Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets, ​providing a lifeline to the struggling cannabis industry.

Reuters • Apr 30, 2026

Cannabis ETFs: Regulatory Momentum Returns Focus

Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.

ETF Trends • Apr 30, 2026

Top U.S. Marijuana Stocks to Watch in April 2026 as the Sector Heats Up

The U.S. cannabis sector continues showing strong long-term growth potential in 2026. The legal market continues to expand across multiple states. In fact, the industry is projected to grow significantly over the next decade. Additionally, more states continue moving toward legalization in some form.

Cannabis Stocks Soared—Than Sank. Here's What Investors Need to Know.

Marijuana-related investments were flying high this morning. Then they reversed course, and quickly.

Investopedia • Apr 23, 2026